-
Ice-cool Rybakina beats Sabalenka in tense Australian Open final
-
Pakistan attacks kill 15, dozens of militants dead: official
-
Ten security officials, 37 militants killed in SW Pakistan attacks: official
-
Epstein survivors say abusers 'remain hidden' after latest files release
-
'Full respect' for Djokovic but Nadal tips Alcaraz for Melbourne title
-
Wollaston goes back-to-back in the Cadel Evans road race
-
Women in ties return as feminism faces pushback
-
Ship ahoy! Prague's homeless find safe haven on river boat
-
Britain's Starmer ends China trip aimed at reset despite Trump warning
-
Carlos Alcaraz: rare tennis talent with shades of Federer
-
Novak Djokovic: divisive tennis great on brink of history
-
History beckons for Djokovic and Alcaraz in Australian Open final
-
Harrison, Skupski win Australian Open men's doubles title
-
Epstein offered ex-prince Andrew meeting with Russian woman: files
-
Jokic scores 31 to propel Nuggets over Clippers in injury return
-
Montreal studio rises from dark basement office to 'Stranger Things'
-
US government shuts down but quick resolution expected
-
Mertens and Zhang win Australian Open women's doubles title
-
Venezuelan interim president announces mass amnesty push
-
China factory activity loses steam in January
-
Melania Trump's atypical, divisive doc opens in theatres
-
Bad Bunny set for historic one-two punch at Grammys, Super Bowl
-
Five things to watch for on Grammys night Sunday
-
Venezuelan interim president proposes mass amnesty law
-
Rose stretches lead at Torrey Pines as Koepka makes cut
-
Online foes Trump, Petro set for White House face-to-face
-
Seattle Seahawks deny plans for post-Super Bowl sale
-
US Senate passes deal expected to shorten shutdown
-
'Misrepresent reality': AI-altered shooting image surfaces in US Senate
-
Thousands rally in Minneapolis as immigration anger boils
-
US judge blocks death penalty for alleged health CEO killer Mangione
-
Lens win to reclaim top spot in Ligue 1 from PSG
-
Gold, silver prices tumble as investors soothed by Trump Fed pick
-
Ko, Woad share lead at LPGA season opener
-
US Senate votes on funding deal - but shutdown still imminent
-
US charges prominent journalist after Minneapolis protest coverage
-
Trump expects Iran to seek deal to avoid US strikes
-
US Justice Dept releases documents, images, videos from Epstein files
-
Guterres warns UN risks 'imminent financial collapse'
-
NASA delays Moon mission over frigid weather
-
First competitors settle into Milan's Olympic village
-
Fela Kuti: first African to get Grammys Lifetime Achievement Award
-
Cubans queue for fuel as Trump issues oil ultimatum
-
'Schitt's Creek' star Catherine O'Hara dead at 71
-
Curran hat-trick seals 11 run DLS win for England over Sri Lanka
-
Cubans queue for fuel as Trump issues energy ultimatum
-
France rescues over 6,000 UK-bound Channel migrants in 2025
-
Surprise appointment Riera named Frankfurt coach
-
Maersk to take over Panama Canal port operations from HK firm
-
US arrests prominent journalist after Minneapolis protest coverage
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
N.Fournier--BTB